Genetic Technologies Acquires Beast Cancer Risk Test

Genetic Technologies has acquired certain assets from US-based Perlegen Sciences, with the main asset being the BrevaGen breast cancer risk test. In addition to the test, GTG has acquired a suite of granted patents that are valid to 2022 which augment and extend the company’s current non-coding patent portfolio.

This product fulfils an unmet need by better classifying women at moderate risk of breast cancer who would potentially benefit from preventive therapy or more intensive monitoring.

Preventive therapy has been shown to be 50 percent successful in preventing cancer in at-risk women.

The test combines population risk factors based on the Gail Score with validated genetic risk factors to give an integrated, personalized breast cancer risk assessment.

GTG intends to launch the test first in the US and Australia in the second half of 2010, followed by a worldwide rollout. The proposed rollout has been market researched and mapped; with the marketing collateral compiled and ready to deploy.

The company has already identified first customers, key opinion leaders and the sales team, and a US reimbursement strategy is in place.